Bactiguard Holding AB (publ) (BACTI-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bactiguard Holding AB (publ) (BACTI-B) has a cash flow conversion efficiency ratio of -0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.43 Million ≈ $-799.91K USD) by net assets (Skr311.60 Million ≈ $33.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bactiguard Holding AB (publ) balance sheet independence to measure how much of total assets are equity-financed.
Bactiguard Holding AB (publ) - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Bactiguard Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Bactiguard Holding AB (publ) (BACTI-B) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Bactiguard Holding AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bactiguard Holding AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Neo-Concept International Group Holdings Limited Ordinary Shares
NASDAQ:NCI
|
0.008x |
|
Global Education Limited
NSE:GLOBAL
|
0.078x |
|
iNtRON Biotechnology Inc
KQ:048530
|
-0.013x |
|
Solidion Technology Inc.
NASDAQ:STI
|
0.017x |
|
LEFORM
KLSE:0266
|
0.111x |
|
Concejo AB (publ)
ST:CNCJO-B
|
-0.030x |
|
R K Swamy Limited
NSE:RKSWAMY
|
0.010x |
|
Elin Electronics Limited
NSE:ELIN
|
0.065x |
Annual Cash Flow Conversion Efficiency for Bactiguard Holding AB (publ) (2009–2025)
The table below shows the annual cash flow conversion efficiency of Bactiguard Holding AB (publ) from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Bactiguard Holding AB (publ) (BACTI-B) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr314.93 Million ≈ $33.89 Million |
Skr-1.49 Million ≈ $-160.02K |
-0.005x | -106.20% |
| 2024-12-31 | Skr328.34 Million ≈ $35.33 Million |
Skr24.99 Million ≈ $2.69 Million |
0.076x | +151.36% |
| 2023-12-31 | Skr353.18 Million ≈ $38.01 Million |
Skr-52.33 Million ≈ $-5.63 Million |
-0.148x | -2498.76% |
| 2022-12-31 | Skr495.71 Million ≈ $53.35 Million |
Skr3.06 Million ≈ $329.52K |
0.006x | -53.91% |
| 2021-12-31 | Skr541.45 Million ≈ $58.27 Million |
Skr7.26 Million ≈ $780.86K |
0.013x | +612.72% |
| 2020-12-31 | Skr373.35 Million ≈ $40.18 Million |
Skr702.00K ≈ $75.55K |
0.002x | -98.65% |
| 2019-12-31 | Skr386.69 Million ≈ $41.61 Million |
Skr53.98 Million ≈ $5.81 Million |
0.140x | +410.15% |
| 2018-12-31 | Skr370.82 Million ≈ $39.91 Million |
Skr-16.69 Million ≈ $-1.80 Million |
-0.045x | -384.84% |
| 2017-12-31 | Skr387.11 Million ≈ $41.66 Million |
Skr6.12 Million ≈ $658.29K |
0.016x | +149.70% |
| 2016-12-31 | Skr390.33 Million ≈ $42.01 Million |
Skr-12.41 Million ≈ $-1.34 Million |
-0.032x | +36.16% |
| 2015-12-31 | Skr417.44 Million ≈ $44.92 Million |
Skr-20.79 Million ≈ $-2.24 Million |
-0.050x | +27.72% |
| 2014-12-31 | Skr518.71 Million ≈ $55.82 Million |
Skr-35.74 Million ≈ $-3.85 Million |
-0.069x | +78.45% |
| 2013-12-31 | Skr140.95 Million ≈ $15.17 Million |
Skr-45.07 Million ≈ $-4.85 Million |
-0.320x | -13.00% |
| 2012-12-31 | Skr144.60 Million ≈ $15.56 Million |
Skr-40.92 Million ≈ $-4.40 Million |
-0.283x | -1883.43% |
| 2011-12-31 | Skr187.86 Million ≈ $20.22 Million |
Skr-2.68 Million ≈ $-288.41K |
-0.014x | -107.36% |
| 2010-12-31 | Skr292.61 Million ≈ $31.49 Million |
Skr56.71 Million ≈ $6.10 Million |
0.194x | -22.88% |
| 2009-12-31 | Skr317.39 Million ≈ $34.16 Million |
Skr79.76 Million ≈ $8.58 Million |
0.251x | -- |
About Bactiguard Holding AB (publ)
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company also has a portfolio of wound management … Read more